Abdera Therapeutics welcomes Eric Dobmeier to its Board of Directors and welcomes Dr- Philippe Bishop to its Management Team

– USA, CA –  Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced the appointment of Eric Dobmeier, J.D. to its Board of Directors, while Dr- Philippe Bishop (M.D.) is joining as Chief Medical Officer.

“We are thrilled to welcome Philippe and Eric to Abdera. Philippe brings an extensive track record in oncology drug development, which will be instrumental as we prepare to advance ABD-147 targeting DLL3 into the clinic. Coupled with Eric’s extensive company building and corporate development expertise, these additions supplement our ongoing effort to build Abdera into a leading radiopharmaceutical company and advance potential best-in-class new cancer medicines,” said CEO, Lori Lyons-Williams. 

About Eric Dobmeier

Mr. Dobmeier is an executive and board member with more than 20 years of experience in the biotechnology industry. Most recently, he served as president and CEO of Chinook Therapeutics through its acquisition by Novartis in 2023 for up to $3.5 billion. Before Chinook, Mr. Dobmeier served as president and CEO of Silverback Therapeutics and held successive leadership positions over 15 years at Seagen (acquired by Pfizer for $43 billion), including COO and CBO. While at Seagen, he was directly involved in raising more than $1.2 billion and completed multiple corporate alliances with leading biotechnology and pharmaceutical companies. He currently serves on the boards of Structure Therapeutics and Atara Therapeutics.

Mr. Dobmeier earned his J.D. from the University of California, Berkeley School of Law, and his undergraduate degree from Princeton University.

“Abdera’s next-generation radiopharmaceutical platform is based on compelling science and has generated promising preclinical proof-of-concept data in a variety of tumor models,” added Mr. Dobmeier. “I look forward to working with the rest of the board and leadership team as Abdera prepares to transition into a clinical-stage company and enter its next phase of growth.”

About Dr. Philippe Bishop

Dr. Bishop previously served as CMO of Atreca, a clinical-stage, oncology-focused biotechnology company. Before Atreca, Dr. Bishop served as CMO of Clover Biopharmaceuticals and was EVPt and CMO at aratinga.bio. Before founding aratinga.bio in 2017, Dr. Bishop was SVP of hematology/oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson, and Sanofi-Aventis. Dr. Bishop previously held leadership positions at the U.S. Food and Drug Administration and the National Institutes of Health.

Dr. Bishop received his M.D. from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute.

About Abdera

Abdera Therapeutics is a biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Abdera’s Radio Optimized Vector Engineering platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells. Abdera’s lead program targets DLL3 for the treatment of small-cell lung cancer and other solid tumors.

SOURCE: https://abderatx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.